BMC Medical Imaging

OCT 21, 2026 · JOURNAL ARTICLE

Impact of reduced scan extent on tumor detection in 68Ga-PSMA PET/CT for biochemical recurrence of prostate cancer

BMC Medical Imaging

Abstract Background PSMA PET/CT plays an important role in biochemically recurrent prostate cancer (BCR-PCa). In general, PET/CT is performed as a limited or true whole-body examin

OCT 16, 2026 · JOURNAL ARTICLE

Associations of mammographic and ultrasonographic features with immunohistochemistry-defined surrogate subtypes of breast cancer: a single-center retrospective study

BMC Medical Imaging

Abstract Background This study aimed to evaluate the associations of mammographic and ultrasonographic features with histopathological characteristics and immunohistochemistry-defi

OCT 12, 2026 · JOURNAL ARTICLE

Mammography-based deep learning radiomics for predicting HER2 expression in breast cancer: a dual-center study with focus on HER2-low status

BMC Medical Imaging

Abstract Background Accurate preoperative assessment of HER2 status is critical for guiding targeted therapy, but conventional biopsy-based methods are invasive and limited by tumo

SEP 30, 2026 · JOURNAL ARTICLE

Deep learning-based large-scale pan-cancer multiple biomarkers prediction using RIDGE with pathological images

BMC Medical Imaging

Abstract Background Molecular profiling tests currently relies significantly on genomics or transcriptomics analysis, leading a prolonged turnaround time and higher costs procedure

SEP 7, 2026 · JOURNAL ARTICLE

Predicting acquired T790M mutations in non-small cell lung cancer after EGFR-TKI therapy: integration of delta-radiomics and clinical characteristics with SHAP interpretation

BMC Medical Imaging

Retrospective, single-centre study with modest sample size and surrogate endpoint (mutation status prediction); requires prospective multicentre validation before clinical use, as stated by the authors.

SEP 4, 2026 · JOURNAL ARTICLE

Associations of baseline [18F]FDG PET/CT metabolic parameters with the efficacy of neoadjuvant immunotherapy plus concurrent chemoradiotherapy in patients with locally advanced gastric adenocarcinoma: a post hoc analysis of the Neo-PLANET phase II trial

BMC Medical Imaging

Post hoc analysis of a phase II trial with small sample (n=29) and surrogate/exploratory endpoints; findings are hypothesis-generating and require validation in larger populations.

AUG 8, 2026 · JOURNAL ARTICLE

Optimal timing of post-therapeutic [131I]NaI whole-body scintigraphy in predominantly low- and intermediate-risk differentiated thyroid cancer: a secondary analysis of prospectively acquired data and a structured literature review

BMC Medical Imaging

A well-designed secondary analysis of prospectively acquired imaging data with independent expert assessment and rigorous statistical methods, but limited to a single-centre cohort of 35 patients evaluating a surrogate imaging quality endpoint rather than clinical outcomes.